To address conflicting reports about the cardiovascular safety of DPP-4 inhibitors, researchers performed a large retrospective cohort study.
Intensive Rx Similar to Standard Care for Preventing CV Events in T2D
More intensive reduction of A1c, lipids, and blood pressure did, however, result in a significantly reduced rate of cerebrovascular events.
AACE/ACE Focus on Lipids: 2017 Consensus Guidelines
The AACE/ACE 2017 recommendations on lipid management renew focus on LDL-C targets, and go far lower than any group has ventured to date.
SGLT2 Inhibitor Offers CV, Renal Protection in High-risk Patients
Significant reductions were seen in MACE, renal disease progression in patients with high CV risk taking canagliflozin.
What Can the “B” Key Do For Your Next Presentation?
This tip and 4 others can help you deliver a message that resonates.
Impact of Ethnicity, Gender on Skin Autoflourescence and Risk for CV, DM
A new study evaluates the impact of ethnicity on skin autoflourescence used to measure accumulation of atherogenic glycated proteins.
The Revised Cholesterol Guidelines
What about those patients who fall into the "gray zone"?
The Artificial Sweetener Paradox: Weight Gain and Metabolic Dysfunction?
A new meta-analysis finds that routine intake of artificial sweeteners is linked to the opposite of the intended effect.
Stress Reduction Lowers Glucose Levels in Obese Women
Mindfulness: a potential intervention for T2DM?
Quiz: The 2017 AACE/ACE Lipid Management and CVD Prevention Guidelines
The 2017 lipid management guidelines have met both accolades and controversy. Take our quick quiz on the updates.
Beta Blockers Heighten Risk of CV Events in T2DM
Post-hoc analysis of ACCORD trial data suggests the indication of beta blocker therapy in T2DM patients be more closely examined.